Treatment‑associated severe thrombocytopenia affects survival rate in esophageal cancer patients undergoing concurrent chemoradiotherapy.
Indian J Cancer
;
2015 July-Sept; 52(3): 454-460
Artigo
em Inglês
| IMSEAR
| ID: sea-173972
ABSTRACT
BACKGROUND:
Esophageal cancer is commonly treated with surgery, concurrent chemoradiotherapy (CCRT), or a combination of both. The correlation between the hematological parameters during CCRT and early survival of esophageal cancer has not been fully evaluated. MATERIALS ANDMETHODS:
We analyzed the records of 65 esophageal cancer patients treated by CCRT between 2007 and 2010 retrospectively. The association between CCRT‑associated myelosuppression, demographic variables, and survival rates were analyzed by univariate and multivariate analysis.RESULTS:
The univariate analysis showed that tumor extent of T3-4, a higher stage of tumor, a lower albumin level, grade 3 or higher anemia and thrombocytopenia, and interruptions in treatment affected survival rates. Further, the multivariate analysis revealed that stage IV (P = 0.030) is an independently negative prognostic factor for a one‑year survival rate. Stage IV (P = 0.035), tumor extent of T3-4 (P = 0.002), and grade 3-4 thrombocytopenia (P = 0.015) are independently negative prognostic factors for a two‑year survival rate.CONCLUSIONS:
Severe decrease in platelet count during CCRT independently affects survival of esophageal cancer patients in addition to stage of the tumor.
Texto completo:
DisponíveL
Índice:
IMSEAR (Sudeste Asiático)
Tipo de estudo:
Estudo prognóstico
Idioma:
Inglês
Revista:
Indian J Cancer
Ano de publicação:
2015
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS